Employee stock option

NorthWest Copper Announces Support for the Company’s Board Nominees From Leading Proxy Advisory Firm ISS

Retrieved on: 
Thursday, September 7, 2023

The Company thanks its shareholders for the strong voting support that the incumbent directors have received so far.

Key Points: 
  • The Company thanks its shareholders for the strong voting support that the incumbent directors have received so far.
  • Further, NorthWest advised that the activist group (the “Activist Group”) unsuccessfully attempted to recruit NorthWest’s Chair and NorthWest’s Interim President and CEO.
  • ISS, which is recognized as a leading independent proxy voting and corporate governance advisory firm in both Canada and the United States, recommends that shareholders vote FOR the incumbent Board and all Management Proposals.
  • NorthWest urges shareholders to vote only the BLUE proxy FOR NorthWest’s seven Director nominees, all of whom are shareholders.

Notice of Annual General Meeting in NeoDynamics AB (Publ)

Retrieved on: 
Monday, April 24, 2023

559014-9117 (the "Company") are hereby convened to the annual general meeting on Tuesday 23 May 2023 at 15.00 at the Company's premises at Lejonvägen 14, Lidingö.

Key Points: 
  • 559014-9117 (the "Company") are hereby convened to the annual general meeting on Tuesday 23 May 2023 at 15.00 at the Company's premises at Lejonvägen 14, Lidingö.
  • Shareholders who wish to participate in the general meeting must:
    notify his/her/its intention to attend the general meeting to the Company no later than Friday 19 May 2023, by mail to NeoDynamics AB (publ), Lejonvägen 14, 181 32 Lidingö, Sweden or by e-mail to [email protected] .
  • Alternatively, the original power of attorney and certificate of registration may be brought and presented at the general meeting.
  • The board of directors proposes that the annual general meeting authorizes the board of directors, for the time until the next annual general meeting, whether on one or several occasions, to resolve on issues of shares, warrants and/or convertible instruments.

Chargebee Earns 2022 US Great Place to Work Certification™

Retrieved on: 
Wednesday, June 22, 2022

This year, 96% of employees said its a great place to work 39% points higher than the average U.S. company.

Key Points: 
  • This year, 96% of employees said its a great place to work 39% points higher than the average U.S. company.
  • Great Place to Work Certification isnt something that comes easily it takes ongoing dedication to the employee experience, said Sarah Lewis-Kulin, vice president of global recognition at Great Place to Work.
  • Were excited to become Great Place to Work Certified in the US, following our previous certification in India at the end of last year, said RU Srinivas, Senior Vice President of People at Chargebee.
  • According to Great Place to Work research , job seekers are 4.5 times more likely to find a great boss at a Certified great workplace.

Maverick FX Transforms to Maverick Currencies

Retrieved on: 
Monday, January 3, 2022

SALT LAKE CITY, Jan. 3, 2022 /PRNewswire/ -- Maverick FX, the foreign currency trading division of the top proprietary trading firm, Maverick Trading, announced that it will be operating under the name Maverick Currencies effective January 1st, 2022.

Key Points: 
  • SALT LAKE CITY, Jan. 3, 2022 /PRNewswire/ -- Maverick FX, the foreign currency trading division of the top proprietary trading firm, Maverick Trading, announced that it will be operating under the name Maverick Currencies effective January 1st, 2022.
  • Previously, Maverick Trading had authorized its traders to trade Bitcoin futures and futures options in its Stock/Options division.
  • Maverick Trading's CEO, Darren Fischer commented at length: "There were two driving forces behind this decision.
  • About Maverick Currencies: Maverick Currencies is the currency trading division of the premier proprietary trading firm, Maverick Trading.

Welcome to attend MAG Interactive AB (publ)'s Annual General Meeting

Retrieved on: 
Thursday, December 9, 2021

STOCKHOLM, Dec. 9, 2021 /PRNewswire/ --MAG Interactive AB (publ) hereby gives notice of its annual general meeting to be held at MAG Interactive AB (publ)'s premises at Drottninggatan 95A, Stockholm, on Wednesday 19 January 2022 at 14:00 CET.

Key Points: 
  • STOCKHOLM, Dec. 9, 2021 /PRNewswire/ --MAG Interactive AB (publ) hereby gives notice of its annual general meeting to be held at MAG Interactive AB (publ)'s premises at Drottninggatan 95A, Stockholm, on Wednesday 19 January 2022 at 14:00 CET.
  • The personal data obtained from the share register maintained by Euroclear Sweden, the notification of participation at the annual general meeting and the information regarding proxies and assistants will be used for registration, preparation of the voting register for the annual general meeting and, where applicable, minutes from the annual general meeting.
  • Opening of the meeting and election of the chairman of the annual general meeting.
  • Therefore, the board of directors proposes that the annual general meeting resolves to issue no more than 264,946 warrants of series 2022/2025:3.

Allogene Therapeutics Reports Second Quarter 2021 Financial Results

Retrieved on: 
Wednesday, August 4, 2021

SOUTH SAN FRANCISCO, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today provided a corporate update and reported second quarter 2021 financial results for the quarter ended June 30, 2021.

Key Points: 
  • Initial Clinical Readout Expected in 2022
    Appointed Liz Barrett and Vicki Sato, Ph.D., Executives with Significant Strategic and Commercial Expertise, to the Board of Directors
    State-of-the-Art cGMP Manufacturing Facility in Newark, California to Support Industrys First Allogeneic Pivotal Trial and Future Commercial Launch
    Ended Second Quarter with$913 Millionin Cash, Cash Equivalents and Investments
    SOUTH SAN FRANCISCO, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc.(Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) therapies for cancer, today provided a corporate update and reported second quarter 2021 financial results for the quarter ended June 30, 2021.
  • Research and development expenses were$52.3 millionfor the second quarter of 2021, which includes$10.5 millionof non-cash stock-based compensation expense.
  • General and administrative expenses were$18.8 millionfor the second quarter of 2021, which includes$10.6 millionof non-cash stock-based compensation expense.
  • Net loss for the second quarter of 2021 was$70.9 million, or$0.53per share, including non-cash stock-based compensation expense of$21.1 million.

Cross River Announces Grant of Stock Options

Retrieved on: 
Friday, July 30, 2021

Vancouver, British Columbia--(Newsfile Corp. - July 29, 2021) - Cross River Ventures Corp. (CSE: CRVC) ("Cross River" or the "Company") today announced that it has awarded incentive stock options pursuant to its stock option plan, to various directors, officers and consultants of the Company, to purchase up to an aggregate of 1,000,000 common shares of the Company.

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - July 29, 2021) - Cross River Ventures Corp. (CSE: CRVC) ("Cross River" or the "Company") today announced that it has awarded incentive stock options pursuant to its stock option plan, to various directors, officers and consultants of the Company, to purchase up to an aggregate of 1,000,000 common shares of the Company.
  • The stock options are exercisable at a price of $0.20 per share and expire two years from the (July 28, 2021) date of grant.
  • Cross River Ventures Corp. is a gold exploration company focused on the development of top tier exploration properties in premier mining districts.
  • Cross River's common shares trade under the symbol "CRVC" on the CSE.

Heliostar Metals Announces Stock Option Grant

Retrieved on: 
Thursday, July 29, 2021

Vancouver, British Columbia--(Newsfile Corp. - July 29, 2021) - Heliostar Metals Limited (TSXV: HSTR) (OTCQX: HSTXF) (FRA: RGG1) ("Heliostar" or the "Company") announces that it has granted to an officer, employee and new consultants of the Company stock options (the "Options") exercisable to acquire up to a total of 220,000 common shares under the Company's Stock Option Plan in accordance with the terms of the Company's stock option plan.

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - July 29, 2021) - Heliostar Metals Limited (TSXV: HSTR) (OTCQX: HSTXF) (FRA: RGG1) ("Heliostar" or the "Company") announces that it has granted to an officer, employee and new consultants of the Company stock options (the "Options") exercisable to acquire up to a total of 220,000 common shares under the Company's Stock Option Plan in accordance with the terms of the Company's stock option plan.
  • The Options are exercisable for a period of five years at a price of $1.00 per share and will vest 1/3 immediately; 1/3 after 12 months from the date of grant; and 1/3 after 24 months from the date of grant.
  • They are exercisable for a period of five years from the date of the grant and are subject to the policies of the TSX Venture Exchange.
  • Heliostar is a well-financed junior exploration and development Company with a portfolio of high-grade gold projects in Alaska and Mexico.

Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, July 29, 2021

Second quarter 2021 GAAP net income was $26.5 million, compared to $28.3 million in the second quarter of 2020.

Key Points: 
  • Second quarter 2021 GAAP net income was $26.5 million, compared to $28.3 million in the second quarter of 2020.
  • Excluding non-cash expenses related to stock-based compensation and the utilization of deferred tax assets, together with related income tax effects, non-GAAP net income in the second quarter was $38.2 million, compared to $39.7 million in the second quarter of 2020.
  • Second quarter operating expenses were $59.6 million, compared to $53.3 million in the second quarter of 2020, due to increased employee compensation expenses, commercial spending, spending on clinical trials in Cushings syndrome and pre-clinical activities.
  • Our second quarter results reflect the fact that physicians are seeing their patients more frequently, which allows them to diagnose and optimally treat those who have Cushings syndrome.

Flex Reports First Quarter Fiscal 2022 Results

Retrieved on: 
Thursday, July 29, 2021

We compensate for the limitations of non-GAAP financial measures by relying upon GAAP results to gain a complete picture of the Company's performance.

Key Points: 
  • We compensate for the limitations of non-GAAP financial measures by relying upon GAAP results to gain a complete picture of the Company's performance.
  • Since we find these measures to be useful, we believe that investors benefit from seeing results "through the eyes" of management in addition to seeing GAAP results.
  • In addition, the Company believes it is useful to investors to understand the specific impact stock-based compensation expense has on its operating results.
  • During the first quarter of fiscal year 2021, the Company accrued for certain loss contingencies where losses are considered probable and estimable.